A potent and selective ligand for the human cannabinoid CB2 receptor. Inhibits LPS-induced COX-2 induction. Also inhibits LPS-induced monocytic cell neurotoxicity.
Product Details
| Formula: | C23H23ClN2O4 |
| |
| MW: | 426.9 |
| |
| CAS: | 2854-32-2 |
| |
| Purity: | ≥98% (TLC) |
| |
| Appearance: | Off-white solid. |
| |
| Solubility: | Soluble in DMSO(25mg/ml) or DMF(25mg/ml). |
| |
| Shipping: | Ambient |
| |
| Long Term Storage: | Ambient |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
BML-190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: signalling via cAMP and inositol phosphates: D. C. New, et al.; FEBS Lett.
536, 157 (2003),
Abstract;
Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor: A. Klegeris, et al.; Br. J. Pharmacol.
139, 775 (2003),
Abstract;
Full Text
Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids: Y. H. Chang, et al.; J. Cell. Biochem.
81, 715 (2001),
Abstract;
